The neo-antigens in the tumor, presented by MHC molecules, can potentially be recognized by the endogenous T cell repertoire, causing increased T cell influx and a better overall response rate to therapeutics (14, 63, 91). The gene discussed is HLA-C; the disease is neoplasm.